



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** October 23, 2009

**To:** Primary Clinical Research Associates

**From:** Janis Wobschall  
Research Protocol Specialist

**Re:** N0779, Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib PS-341) in Patients with Recurrent Glioblastoma Multiforme

The Registration Eligibility Checklist has been updated as follows:

<b>Form Title</b>	<b>Brief Description of Edit</b>
Registration (Step 2) Eligibility Checklist	<p><b>Read:</b></p> <ul style="list-style-type: none"><li>• Use of valproic acid, another histone deacetylase inhibitor, for <math>\leq 2</math> weeks prior to registration.</li></ul> <p><b>Now reads:</b></p> <ul style="list-style-type: none"><li>• Use of valproic acid, another histone deacetylase inhibitor, for <math>\leq 7</math> days prior to registration.</li></ul>

If you have any questions, please feel free to contact me.

Enclosure